Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in China

Abstract Objective Efgartigimod, a neonatal Fc receptor antagonist, facilitates antibody degradation including pathogenic IgGs. The ADAPT study demonstrated the tolerability and efficacy of efgartigimod in the treatment of generalized myasthenia gravis (gMG). However, very limited evidence is availa...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sushan Luo, Qilong Jiang, Wenshuang Zeng, Qinzhou Wang, Zhangyu Zou, Yanyan Yu, Daojun Hong, Quantao Zeng, Song Tan, Zhouao Zhang, Yong Zhang, Xiuming Guo, Jing Chen, Zhongyan Zhao, Shixiong Huang, Jianquan Shi, Ying Chen, Lei Du, Chong Yan, Jianying Xi, Jie Song, Chongbo Zhao, the Chinese Myasthenia Gravis Collaborating Group (CMGCG)
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2024-08-01
Col·lecció:	Annals of Clinical and Translational Neurology
Accés en línia:	https://doi.org/10.1002/acn3.52142
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!